Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Aminosalicylates
8 evidence topics · 4 sources
Recommendations against 5-ASA added to advanced therapy: ACG 2025 guideline
Recommendations for 5-ASA in mildly to moderately active disease: ACG 2025 guideline
Recommendation to stop 5-ASA after escalation: AGA 2024 living guideline
“13. In adult outpatients with moderate-to-severe UC, who have failed 5-ASAs, and have escalated to therapy with immunomodulators or advanced therapies, the AGA suggests stopping 5-ASAs. [Conditional recommendation, low certainty of evidence]” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Large observational studies have suggested no difference in the risk of adverse clinical outcomes between patients who continue vs. stop 5-ASA after starting advanced therapies or immunomodulators99–101.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The guideline panel also acknowledged that one proposed benefit of long-term 5-ASA use is potential chemoprevention effect against colorectal cancer, but this remains unproven.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Recommendations for 5-ASA induction, maintenance, and discontinuation: ECCO 2026 guideline
Efficacy of oral 5-ASA versus placebo: ECCO 2026 meta-analysis
Indication of delayed-release mesalamine tablets
Remission at Week 8 in two placebo-controlled induction trials of delayed-release mesalamine tablets
| Dose | Study 1 (n=262) n/N (%) | Study 2 (n=255) n/N (%) |
|---|---|---|
| Mesalamine 2.4 g/day | “30/88 (34)” | “34/84 (41)” |
| Mesalamine 4.8 g/day | “26/89 (29)” | “35/85 (41)” |
| Placebo | “11/85 (13)” | “19/86 (22)” |